---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-26-000019"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-08-28T12:30:48+00:00"
generated_at: "2026-08-28T12:35:24.994960+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# iBio FY2026: cash $88M, R&D up to $19.6M, IBIO-600 Phase 1 on track

## Summary
- Revenue $0.1M (down from $0.4M); R&D expenses $19.6M vs $8.3M; G&A $10.6M.
- Cash and investments $88.0M as of June 30, 2026; runway extended into FY2028.
- IBIO-600 Phase 1 dosed 31 of 32 participants; advancing to multiple ascending dose.
- IBIO-610 and IBIO-800 in IND-enabling studies; in-licensed AstralBio amylin receptor program.
- Financings: $100M public offering (Aug 2025), $26M private placement (Jan 2026), $100M ATM with Jefferies.

## SEC filing metadata
- accession: 0001420720-26-000019
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-08-28T12:30:48+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000019/0001420720-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000019/ibio-20260828x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-26-000019
- JSON: https://secwatch.observer/filing/0001420720-26-000019.json
- Plain text: https://secwatch.observer/filing/0001420720-26-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.